MAPT and Alzheimer disease: In this context, the reduction in Aβ42, along with alterations in the Aβ42/Aβ40 ratio, t-tau, and p-tau levels, is commonly referred to as an Alzheimer’s signature because it allows for the detection of AD at an early stage [81].